can the cd43 molecule be considered as a therapeutic
play

CAN THE CD43 MOLECULE BE CONSIDERED AS A THERAPEUTIC TAGET? Yvonne Rosenstein Instituto de Biotecnologia, UNAM CD43: the molecule and its signaling capacities favors a Th1 differentiation pattern and contributes to the decision making

0 downloads 13 Views 908 KB Size Report
  1. CAN THE CD43 MOLECULE BE CONSIDERED AS A THERAPEUTIC TAGET? Yvonne Rosenstein Instituto de Biotecnologia, UNAM

  2. CD43: � the molecule and its signaling capacities � favors a Th1 differentiation pattern and contributes to the decision making process of T lymphocytes � participates in non-lymphoid tumors

  3. CD43: � the molecule and its signaling capacities � favors a Th1 differentiation pattern and contributes to the decision making process of T lymphocytes � participates in non-lymphoid tumors

  4. serine, CD43 threonine and proline residues CD4 45 nM 60% of the molecular mass Sialic acid Expression: Galactose •All lymphoid cells N-acetylgalactosamine (except erythrocytes), • Epithelial tumors 115 kDa/135 kDa 123 aa Intracytoplasmic region: -no enzymatic activity - no tyrosine residues -serine and threonine residues potentially phosphorylable -Proline rich region -ERMs binding region

  5. L-selectin CD2 CD4 HSA 2 4 Sialyl Lex E- CD33 SiGlec-1 selectin PSGL-1 CD83 ICAM-1 LF A-1 CD43 MHC I CD8 Transialidase T. cruzi S. gordinii ACTIVATION Galectin-1 Anti-CD43 Abs CD7 CD45 M. tuberculosis GM 1 CD4 CD3 HOMING ADHESION CD43 INFLAMMATION APOPTOSIS PROLIFERATION ANTI- ADHESION CYTOSKELETON REARRENGEMENTS

  6. CD3 CD43 ζ ζ Y Y Y Y Y Y Y Y Y Y Y Y vía PLC γ vía Rho Family vía Ras vía PI3K PIP Shc Rac R a s PIP Lck PLC γ PIP2 S h c 2 3 PI3K GTP GTP Grb2 G r b 2 Vav S o s IP3 DAG GTP GTP R a f PDK1 PKC P M e k AKT ++ Ca p38 JNK P E r k ER mTOR Calcineurin Jun Fos NF κ B AP-1 NFA T TRANSCRIPCIÓN DE GENES

  7. CD43: � the molecule and its signaling capacities � favors a Th1 differentiation pattern and contributes to the decision making process of T lymphocytes � participates in non-lymphoid tumors

  8. Is the order important? CD43 ERK SHP-1 adapted from Nat. Rev. Mol. Cell Biol. 2000

  9. CD43 engagement prior or at the same time as the T cR results in sustained ERK phosphorylation A Time (min) 0 2 5 10 15 30 60 120 B pERK IgG1/IgG2 Time (min) 5 10 15 30 ERK pJNK IgG1/IgG2 JNK pERK L10 ERK pJNK L10 C JNK pERK OKT3 Time (min) 10 pJNK ERK OKT3 pERK JNK ERK pERK (L10+OKT3) pJNK TPA (L10+OKT3) ERK pJNK JNK JNK pERK pJNK L10-OKT3 L10-OKT3 JNK ERK pJNK OKT3-L10 pERK OKT3-L10 JNK ERK 1 2 3 4 1 2 3 4 5 6 7 8

  10. CD43 CD43 TCR TCR TCR CD3 CD3 CD3 E R Lck Fyn M PI3-K PLC γ 2 CD3 ζ SHP-1 Vav DAG PIP 2 IP3 PKC Ras MAPKs PKC p70S6K ERK JNK Ca ++ Proliferation apoptosis

  11. CD43 signals provided at the same time or prior to those of the TCR prevent the association of SHP-1 to Lck 2h

  12. T cell proliferation vs anergy : the order matters ? IL-2 PRODUCTION 2h 7 d Proliferation 48h IL-2

  13. CD43 prior or at the same time that the TCR prevents CTLA-4 expression Proliferation Anergy - CTLA-4 -No IL-2 2h 48h CTLA-4

  14. Fold change

  15. CD43 signals induce IL-12R , IFN γ R and IFN γ expression

  16. CD43 CD43 CD3 CD3 CTLA-4 Zap-70 Zap-70 Lck Lck CD3 ζ X SHP-1 CBL CD3 ζ CBL-b SHP-1 ERK ERK Downstream Downstream signals signals T-bet PROLIFERA TION PROLIFERA TION CYTOKINES, ETC CD43+TCR TCR-CD43 CD43-TCR

  17. a b a.1 a.2 b.1 b.2 a.1.1 a.1.2

  18. CD43: � the molecule and its signaling capacities � favors a Th1 differentiation pattern and contributes to the decision making process of T lymphocytes � participates in non-lymphoid tumors

  19. T r minos de la # de entradas bœ squeda (PubMed) CD43 997 CD43 & tumor cells 386 CD43 & lymphomas 261 CD43 & skin 88 CD43 & lung 35 CD43 & breast 15 CD43 & colon 13 CD43 & ovary 10 CD43 & cervix 5 CD43 & thyroid 3 CD43 & metastasis 12

  20. CD43 promotes cell transformation Colonies A and D . NIH ‐ 3T3 mock cells. B and E . NIH ‐ 3T3 ‐ CD43WT. C and F . NIH ‐ 3T3 ‐ CD43 Δ IC.

  21. Baeckstrom et al ., 1995; Santamaria et al ., 1996; Sikut et al ., 1997; Kadaja et al ., 2004; Ziprin et al ., 2004

  22. CD43 enhances wound-healing

  23. Conclusions • CD43 senses the cell’s environment • The quality of the cell’s response can reflect the order with which a cell perceives different signals – Cbl c pSer vs Cblc pY & SHP-1 dependent mechanism • CD43 promotes a Th1 response • CD43-mediated signals lead to the synthesis of numerous cytokynes, cheokines and growth factors, both in normal human T cells and in non-lymphoid human tumor cells • CD43 favors transformation/proliferation/locomotion of non lymphoid tumor cells

  24. Instituto de UAEM Biotecnologia Angélica Santana Gustavo Pedraza Erika Melchy Oswaldo López Funding from : DGAPA/UNAM Nora Fierro CONACYT Amiel Olivos Monserrat Sandoval Maria Elena Bravo Nohemi Camacho Cecilia Martinez

Recommend Documents


single molecule bio physics single molecule fluorescence
Single Molecule Bio-Physics Single

Single Molecule Bio-Physics Single Molecule Fluorescence Techniques Single

new family of molecules with oral therapeutic potential
New family of molecules with oral

New family of molecules with oral therapeutic potential in obesity, NASH,

new family of molecules with oral therapeutic potential
New family of molecules with oral

New family of molecules with oral therapeutic potential in NAFLD/NASH,

chemspace 3d shaped fragments description
Chemspace 3D-Shaped Fragments

Chemspace 3D-Shaped Fragments Description The shape of the molecule is an

the efficacy of a commercially available tether molecule
The efficacy of a commercially

The efficacy of a commercially available tether molecule in creating a

cholesterol transporters cholesterol transporters as new
Cholesterol transporters Cholesterol

Cholesterol transporters Cholesterol transporters as new therapeutic targets

new therapeutic uses ntu program
NEW THERAPEUTIC USES (NTU) PROGRAM

NEW THERAPEUTIC USES (NTU) PROGRAM Christine Colvis, Ph.D. June 18, 2015

time out states and transitions
Time outstates and transitions

Time outstates and transitions Spectroscopy transitions between energy states

effect of therapeutic hypercapnia on effect of
Effect of Therapeutic Hypercapnia on

Effect of Therapeutic Hypercapnia on Effect of Therapeutic Hypercapnia on

therapeutic drug therapeutic drug monitoring tdm
Therapeutic Drug Therapeutic Drug

24/08/2017 Therapeutic Drug Therapeutic Drug Monitoring(TDM) Jenna Waldron

detailing and dimensional stability considerations in
Detailing and Dimensional Stability

Detailing and Dimensional Stability Considerations in Spray Polyurethane Foam

sprayable antibacterial film a nanosilver composite
Sprayable Antibacterial Film: a

Sprayable Antibacterial Film: a Nanosilver Composite Nathan Cloeter, Luis

adhesion technology of copper surface for high frequency
Adhesion Technology of Copper Surface

Adhesion Technology of Copper Surface for High Frequency PWBs - FlatBOND GT

chiropractic what is it good for
Chiropractic: What is it good for?

Chiropractic: What is it good for? Current Topics in Chiropractic David

overview of medical polymers polymer pyramid
Overview of Medical Polymers Polymer

Overview of Medical Polymers Polymer Pyramid Confidential Page 2

reactors by surface modification of different
reactors by surface modification of

Improvement of biofilm formation in trickle bed reactors by surface

solving uv mysteries
Solving UV Mysteries Anything that you

Whodat? Whodunit? Solving U V Cu r in g Mysteries with Measurement Jim

selic corp opportunity day
SELIC CORP OPPORTUNITY DAY QUARTER

SELIC CORP OPPORTUNITY DAY QUARTER 3/2017 DATE: November 10, 2017 Selic Corp

background on confluent
Background on Confluent The Primer

A Primer for budding entrepreneurs: I think I have a great idea, now what?

presentation
Presentation ICMA CardTREX Europe 5-6

Presentation ICMA CardTREX Europe 5-6 October 2017 Milan, Italy Innovative

cell adhesion
Cell Adhesion Applica/on of

Cell Adhesion Applica/on of Localized Forces to Cells Adrian

fy17 results presentation
FY17 results presentation Andrew

FY17 results presentation Andrew Rashbass and Colin Jones 22 November 2017